Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

NCT05442216 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Tagraxofusp
DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

Joshua Zeidner

Collaborators

[object Object]
[object Object]